Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

November 17, 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

News Conference News AHA 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

November 17, 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

November 11, 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 07, 2023

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

November 05, 2022

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Black, Hispanic Individuals Bear Pandemic’s Brunt: AHA COVID-19 CVD Registry

News Conference News AHA 2020

Black, Hispanic Individuals Bear Pandemic’s Brunt: AHA COVID-19 CVD Registry

November 18, 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

News Conference News AHA 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

November 15, 2020

SCAPIS: CTA Finds Silent CAD in 42% of Middle-aged Adults

News Conference News AHA 2020

SCAPIS: CTA Finds Silent CAD in 42% of Middle-aged Adults

November 13, 2020

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

November 18, 2019

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

News Conference News AHA 2018

DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors

November 10, 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

November 10, 2018

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.